Similarly, patients with TP53 mutations tended to have shorter median combined cPFS compared with those that were TP53 wild type (P = 0.09), and those with primary uterine tumors tended to have shorter median combined cPFS than those with extrauterine tumors (P = 0.09), even though statistical significance was not met in both cases (Supplementary Fig. S7). This evidence concerns the gene TP53 and tumor of uterus.